A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy.

Trial Profile

A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Carbamazepine (Primary) ; Carbamazepine
  • Indications Epilepsy; Generalised seizures; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 28 Apr 2017 Results assessing the the pharmacokinetics of Capitsol in carbamazepine(CBZ)-treated patients with epilepsy by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results comparing pharmacokinetics of oral carbamazepine (CBZ) and intravenous CBZ in patients by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top